Because IL-6 is an upstream target of STAT3 and elevated IL-6 levels in cancer patients have prognostic significance regardless of the cancer type [148], several compounds targeting IL-6 or IL-6R have been developed and are used for both non-malignant and malignant diseases [149,150]. The gene discussed is STAT3; the disease is cancer.